<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628559</url>
  </required_header>
  <id_info>
    <org_study_id>2009/137</org_study_id>
    <nct_id>NCT04628559</nct_id>
  </id_info>
  <brief_title>Comparison of the Perioperative Effects of Dexmedetomidine and Ketamine Sedation in Septorhinoplasty Operations</brief_title>
  <official_title>Comparison of the Perioperative Effects of Dexmedetomidine and Ketamine Sedation in Septorhinoplasty Operations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karadeniz Technical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karadeniz Technical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized double-blind study aimed to compare the effects of dexmedetomidine and&#xD;
      ketamine on hemodynamic parameters, recovery criteria, and opioid consumption and advers&#xD;
      effects in septorhinoplasty operations. Totally 63 patients were included.&#xD;
&#xD;
      The groups were compared in terms of hemodynamic values, recovery times, postoperative&#xD;
      agitation, sedation, activity, modified Aldrete and pain scores, side-effects and additional&#xD;
      analgesia requirements at postoperative 24h.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 63 patients 18-55 years undergoing septorhinoplasty, who were graded as American&#xD;
      Society of Anesthesiologists physical status were randomly allocated into three groups,&#xD;
      receiving dexmedetomidine (n=21, Group D), ketamine (n=21, Group K) and saline solution&#xD;
      (n=21, Group S). Anesthesia was induced with propofol, cisatracurium and fentanyl.&#xD;
      Maintenance anesthesia was done with 2-2.5% sevoflurane mixture, 50-60% oxygen and N2O. The&#xD;
      groups were compared in terms of hemodynamic values, recovery times, postoperative agitation,&#xD;
      sedation, activity, modified Aldrete and pain scores, side-effects and additional analgesia&#xD;
      requirements at postoperative 24h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2009</start_date>
  <completion_date type="Actual">December 31, 2009</completion_date>
  <primary_completion_date type="Actual">December 30, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>First arm received dexmedetomidine&#xD;
Second arm received ketamine&#xD;
Third arm received saline solution.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The surgeon and observers were all blinded to the patients until the end of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Response to verbal stimulus time</measure>
    <time_frame>0-120 minutes following finishing operation</time_frame>
    <description>Verbal response received when the patient was spoken to</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative additional fentanyl requirement</measure>
    <time_frame>0-120 minutes following initiating operation</time_frame>
    <description>Intraoperative additional fentanyl requirement for pain relief and</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>0-120 minutes</time_frame>
    <description>Heart rate during operation and following operation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Anesthesia</condition>
  <condition>Intravenous Anesthetic Toxicity</condition>
  <arm_group>
    <arm_group_label>Dexmedetomine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients recieving Dexmedetomidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients recieving Ketamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients recieving Saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).</description>
    <arm_group_label>Dexmedetomine</arm_group_label>
    <other_name>Group D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Group K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient graded as American Society of Anesthesiologist (ASA) physical status, I or II&#xD;
&#xD;
          -  Patient subjected to septorhineoplasty operation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having morbid obesity,&#xD;
&#xD;
          -  Patient having yypertension,&#xD;
&#xD;
          -  Patient having Asthma,&#xD;
&#xD;
          -  Patient having neuropsychiatric disease,&#xD;
&#xD;
          -  Patient allergy to the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muge Muge, Assoc Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Medical School of Karadeniz Technical University, Department of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical School of Karadeniz Technical University, Department of Anesthesiology</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karadeniz Technical University</investigator_affiliation>
    <investigator_full_name>Muge Kosucu</investigator_full_name>
    <investigator_title>Clinical Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Perioperative effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

